Cerebrospinal fluid from cognitively impaired patient with acquired immunodeficiency syndrome shows gp120-like neuronal killing in vitro

1989 ◽  
Vol 87 (3) ◽  
pp. 361-362 ◽  
Author(s):  
Jeanine M. Buzy ◽  
Douglas E. Brenneman ◽  
Frederick P. Siegal ◽  
Michael R. Ruff ◽  
Candace B. Pert
Keyword(s):  
Cerebrospinal Fluid ◽  
Acquired Immunodeficiency Syndrome ◽  
Cognitively Impaired ◽  
Impaired Patient ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

scholarly journals Bacterial agents isolated from cerebrospinal fluid of patients with Acquired Immunodeficiency Syndrome (AIDS) and neurological complications

1994 ◽  
Vol 36 (6) ◽  
pp. 491-496 ◽  
Author(s):  
Ilka Maria Landgraf ◽  
Moisés Palaci ◽  
Maria de Fátima Paiva Vieira ◽  
Sueli Yoko Mizuka Ueki ◽  
Maria Conceição Martins ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Acquired Immunodeficiency Syndrome ◽  
Mycobacterium Avium Complex ◽  
Neurological Complications ◽  
Age Group ◽  
Bacterial Agent ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
And Staphylococcus Aureus ◽  
Culture Positive

Cerebrospinal fluid (CSF) samples from 2083 patients with acquired immunodeficiency syndrome (AIDS) and neurological complications were bacteriologically examined during a period of 7 years (1984-1990). The percentage of patients who had at least one bacterial agent cultured from the CSF was 6.2%. Mycobacterium tuberculosis was the most frequently isolated agent (4.3%), followed by Mycobacterium avium complex or MAC (0.7%), Pseudomonas spp (0.5%), Enterobacter spp (0.4%), and Staphylococcus aureus (0.3%). Among 130 culture positive patients, 89 (68.5%) had M. tuberculosis and 15 (11.6%) had MAC. The frequency of bacterial isolations increased from 1988 (5.2%) to 1990 (7.2%), partly due to the increase in MAC isolations. Bacterial agents were more frequently isolated from patients in the age group 21-30 years and from women (p<0.05).

Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome

Blood ◽  
1999 ◽  
Vol 93 (5) ◽  
pp. 1506-1510 ◽  
Author(s):  
Rusung Tan ◽  
Xiaoning Xu ◽  
Graham S. Ogg ◽  
Pokrath Hansasuta ◽  
Tao Dong ◽  
...  
Keyword(s):  
T Cell ◽  
Adoptive Transfer ◽  
Acquired Immunodeficiency Syndrome ◽  
Mononuclear Cells ◽  
Virus Load ◽  
Acquired Immunodeficiency ◽  
Peptide Complexes ◽  
Immunodeficiency Syndrome

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) probably play the major role in controlling HIV replication. However, the value of adoptive transfer of HIV-specific CTL expanded in vitro to HIV+ patients has been limited: this contrasts with the success of CTL therapy in treating or preventing Epstein-Barr virus and cytomegalovirus disease after bone marrow transplantation (BMT). We investigated the fate of expanded HIV-specific CTL clones in vivo following adoptive transfer to a patient with acquired immunodeficiency syndrome (AIDS). Two autologous CTL clones specific for HIV Gag and Pol were expanded to large numbers (>109) in vitro and infused into an HIV-infected patient whose viral load was rising despite antiretroviral therapy. The fate of one clone was monitored by staining peripheral blood mononuclear cells (PBMCs) with T-cell receptor–specific tetrameric major histocompatibility complex (MHC)-peptide complexes. Although the CTL transfer was well tolerated, there were no significant changes in CD4 and CD8 lymphocyte counts and virus load. By tracking an infused clone using soluble MHC-peptide complexes, we show that cells bearing the Gag-specific T-cell receptors were rapidly eliminated within hours of infusion through apoptosis. Thus, the failure of adoptively transferred HIV-specific CTL to reduce virus load in AIDS may be due to rapid apoptosis of the infused cells, triggered by a number of potential mechanisms. Further trials of adoptive transfer of CTL should take into account the susceptibility of infused cells to in vivo apoptosis.

scholarly journals Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome.

1985 ◽  
Vol 76 (5) ◽  
pp. 1959-1964 ◽  
Author(s):  
H W Murray ◽  
K Welte ◽  
J L Jacobs ◽  
B Y Rubin ◽  
R Mertelsmann ◽  
...  
Keyword(s):  
Acquired Immunodeficiency Syndrome ◽  
Interleukin 2 ◽  
In Vitro Response ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

Activation of monocyte-mediated tumoricidal activity in patients with acquired immunodeficiency syndrome.

1985 ◽  
Vol 3 (7) ◽  
pp. 1005-1012 ◽  
Author(s):  
E S Kleinerman ◽  
L M Ceccorulli ◽  
L A Zwelling ◽  
T Twilley ◽  
R B Herberman ◽  
...  
Keyword(s):  
Acquired Immunodeficiency Syndrome ◽  
Mononuclear Cells ◽  
Human Tumor ◽  
Target Cells ◽  
Aids Patients ◽  
Tumoricidal Activity ◽  
Ifn Gamma ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

The purpose of these studies was to determine whether peripheral blood monocytes from acquired immunodeficiency syndrome (AIDS) patients with Kaposi's sarcoma could be activated to lyse human tumor target cells in vitro. Monocytes were isolated and incubated for 24 hours in vitro with either medium (control), a crude mitogen-induced lymphokine preparation (MAF), or endotoxin before the addition of [125I]IUdR-labeled A375 melanoma target cells. Cytolysis was determined 72 hours later. Twelve (100%) of 12 patients tested had monocyte-mediated cytotoxicity values that were comparable to those of normal individuals. Recombinant human gamma interferon (IFN gamma) activated both normal and AIDS monocyte-mediated tumoricidal function only when combined with lypopolysaccharide (LPS). In addition, mononuclear cells from ten AIDS patients were also tested for their ability to secrete MAF and IFN gamma in response to a mitogenic stimulus. Lymphokines generated from all ten patients contained substantial amounts of IFN gamma (100 to 2,500 U/mL); however, three of these ten lymphokine preparations failed to activate normal monocytes to lyse tumor cells. These results suggest that monocyte-mediated tumoricidal function of AIDS patients is intact and thus suggest new approaches for the therapy of AIDS.

Sign in / Sign up

Export Citation Format

Share Document